Drug Profile
Research programme: T-type calcium channel antagonist - Diakron Pharmaceuticals
Alternative Names: DP-3005Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Diakron Pharmaceuticals
- Class Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Angina-pectoris in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in USA
- 18 Aug 2008 Preclinical trials in Angina pectoris in USA (unspecified route)